Viewing the cardiovascular pathogenicity of Lp(a) from the pro-inflammatory side

Vascular Disease Prevention

Volumn 5, Issue 3, 2008, Pages 150-155

  Philips, Binu ^a   Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apolipoprotein(a); Inflammation; Kringle; Lipoprotein(a); Oxidized phospholipids

Indexed keywords

APOLIPOPROTEIN B100; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY RESPONSE; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; DISEASE ACTIVITY; GENE MUTATION; HUMAN; KRINGLE DOMAIN; LIPOPROTEIN BLOOD LEVEL; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; STRUCTURAL HOMOLOGY; THROMBOGENICITY;

EID: 48749106994     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008785133791     Document Type: Review

References (90)

1. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
2. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 34: 2108-2115.
3. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
4. Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003; 49: 1785-1796.
5. Moliterno DJ, Jokinen EV, Miserez AR, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995; 15: 850-855.
6. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 2003; 5: 106-113.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
8. Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-142.
9. Bonen DK, Hausman AM, Hadjiagapiou C, et al. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997; 272: 5659-5667.
10. Edelstein C, Davidson NO, Scanu AM. Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids 1994; 67-68: 135-143.
11. Frank SL, Klisak I, Sparkes RS, et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum Genet 1988; 79: 352-356.
12. Malgaretti N, Acquati F, Magnaghi P, et al. Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region. Proc Natl Acad Sci USA 1992; 89: 11584-11588.
13. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330(6144): 132-137.
14. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93: 2758-2763.
15. Rader DJ, Cain W, Zech LA, et al. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91: 443-447.
16. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
17. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clin Chem 1994; 40: 574-578.
18. Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998; 273: 17793-17800.
19. Knight BL, Perombelon YF, Soutar AK, et al. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87: 227-237.
20. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403-1408.
21. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999; 10: 225-236.
22. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003; 14: 361-366.
23. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-3851.
24. Loscalzo J, Weinfeld M, Fless GM, et al. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-245.
25. Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 33: 301-303.
26. Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-2465.
27. Berge KE, Djurovic S, Muller HJ, et al. Studies on effects of Lp(a) lipoprotein on gene expression in endothelial cells in vitro. Clin Genet 1997; 52: 314-325.
28. Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14: 438-442.
29. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57: 155-162.
30. Sangrar W, Bajzar L, Nesheim ME, et al. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995; 34: 5151-5157.
31. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980-2987.
32. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
33. Davi G, Patrono C. Mechanisms of disease: Platetet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
34. Discepolo W, Wun T, Berglund L. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006; 35: 314-321.
35. Tsironis LD, Mitsios JV, Milionis HJ, et al. Effect of lipoprotein(a) on platelet activation induced by platelet activating factor: role of apolipoprotein(a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 2004; 63: 130-138.
36. Gries A, Gries M, Wurm H, et al. Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol 1996; 16: 648-655.
37. Barre DE. Apoprotein (a) antagonises THE GPIIB/IIIA receptor on collagen and adp-stimulated human platelets. Front Biosci 2004; 9: 404-410.
38. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-4633.
39. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998; 18: 1393-1399.
40. Martinez C, Rivera J, Loyau S, et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost 2001; 85: 686-693.
41. Malle E, Ibovnik A, Stienmetz A, et al. Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb 1994; 14: 345-352.
42. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116: 1832-1844.
43. Edelstein C, Yousef M, Scanu AM. Elements in the C terminus of apolipoprotein (a) responsible for the binding to the tenth type III module of human fibronectin. J Lipid Res 2005; 46: 2673-2680.
44. Kostner GM, Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J 1990; 11 (Suppl E): 184-189.
45. Lou XJ, Boonmark NW, Horrigan FT, et al. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998; 95: 12591-12595.
46. Pillarisetti S, Paka L, Obunike JC, et al. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997; 100: 867-874.
47. Scanu AM, Edelstein C, Klezovitch O. Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix. Trends Cardiovasc Med 1999; 9: 196-200.
48. van der Hoek YY, Sangrar W, Cote GP, et al. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb 1994; 14: 1792-1798.
49. Hoover-Plow J, Khaitan A, Fless GM. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998; 79: 640-648.
50. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
51. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003; 14: 421-430.
52. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo[a] and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32: 317-327.
53. Haberland ME, Fless GM, Scanu AM, et al. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267: 4143-4151.
54. Krempler F, Kostner GM, Roscher A, et al. The interaction of human apoB-containing lipoproteins with mouse peritoneal macrophages: a comparison of Lp(a) with LDL. J Lipid Res 1984; 25: 283-287.
55. Snyder ML, Polacek D, Scanu AM, et al. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem 1992; 267: 339-346.
56. Bottalico LA, Keesler GA, Fless GM, et al. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem 1993; 268: 8569-8573.
57. Keesler GA, Gabel BR, Devlin CM, et al. The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J Biol Chem 1996; 271: 32096-32104.
58. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-2042.
59. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-592.
60. Formato M, Farina M, Spirito R, et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 2004; 24: 129-135.
61. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462.
62. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-1658.
63. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113: 1439-1445.
64. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
65. Allena S, Khan S, Tam S, et al. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J 1998; 12: 1765-1776.
66. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998; 97: 721-728.
67. Poon M, Zhang X, Dunsky K, et al. Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet 1997; 52(5): 308-313.
68. Poon M, Zhang X, Dunsky KG, et al. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514-2519.
69. Haque NS, Zhang X, French DL, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000; 102: 786-792.
70. Ragab MS, Selvaraj P, Sgoutas DS. Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 1996; 123: 103-113.
71. Sotiriou SN, Orlova VV, Al-Fakhri N, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006; 20: 559-561.
72. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000; 247: 371-380.
73. Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-814.
74. Friedman P, Horkko S, Steinberg D, et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 2002; 277: 7010-7020.
75. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-1740.
76. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine- phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003; 278: 52841-52847.
77. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 2001; 276: 46864-46869.
78. Wang N, Tabas I, Winchester R, et al. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996; 271: 8837-8842.
79. Joy ST, Patel PN, Pfaffinger D, et al. Apolipoprotein(a) in the carotid artery plaque: Evidence for proteolytic and proinflammatory modifications. Vasc Dis Prev 2008; 5: 1-8.
80. Gharavi NM, Alva JA, Mouillesseaux KP, et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007; 282: 31460-31468.
81. Moliterno DJ, Lange RA, Meidell RS, et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993; 88: 935-940.
82. Stubbs P, Seed M, Lane D, et al. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998; 19: 1355-1364.
83. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996; 37: 2569-2585.
84. Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol 1992; 70: 945-949.
85. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-1774.
86. Scanu AM, Pfaffinger D, Lee JC, et al. A single point mutation (Trp72 - >Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994; 1227: 41-45.
87. Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2030-2036.
88. Scanu AM. Lp(a) lipoprotein - coping with heterogeneity. N Engl J Med 2000; 349: 2089-2090.
89. Atac IA, Peksel A, Yanardag R, et al. The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. Drug Chem Toxicol 2006; 29: 363-377.
90. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006; 98: 743-745.